EP4615403A1 - Personal care composition - Google Patents

Personal care composition

Info

Publication number
EP4615403A1
EP4615403A1 EP23790589.8A EP23790589A EP4615403A1 EP 4615403 A1 EP4615403 A1 EP 4615403A1 EP 23790589 A EP23790589 A EP 23790589A EP 4615403 A1 EP4615403 A1 EP 4615403A1
Authority
EP
European Patent Office
Prior art keywords
composition
carboxymethyl cysteine
carboxymethyl
weight
coffee
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23790589.8A
Other languages
German (de)
French (fr)
Inventor
Xuelan GU
Tingyan MI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever Global IP Ltd
Unilever IP Holdings BV
Original Assignee
Unilever Global IP Ltd
Unilever IP Holdings BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Global IP Ltd, Unilever IP Holdings BV filed Critical Unilever Global IP Ltd
Publication of EP4615403A1 publication Critical patent/EP4615403A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/522Antioxidants; Radical scavengers

Definitions

  • the present invention relates to a personal care composition
  • a personal care composition comprising a carboxymethyl cysteine compound and coffee seed oil.
  • such composition is capable of providing synergistic antioxidation effect.
  • Oxidative stress may affect our skin in many ways including signs of premature aging such as wrinkles, fine lines, uneven skin tone.
  • TXNRD1 Thioredoxin reductase 1
  • TXNRD1 is an oxidoreductase encoded by the TXNRD1 gene in humans and a member of the antioxidant thioredoxin system.
  • TXNRD1 plays an important role in oxidative stress control. It reduces and activates thioredoxin, an oxidoreductase containing a dithiol-disulfide active site. Thioredoxin binds ROS before they can harm cells and thus protects cells against oxidative stress.
  • the present inventors have recognized there is a need to develop a personal care composition which is capable of improving the gene expression of TXNRD1. Therefore, the present inventors have developed a personal care composition comprising carboxymethyl cysteine compound and coffee seed oil. It was surprisingly found that by combining carboxymethyl cysteine compound with coffee seed oil with weight ratio of the carboxymethyl cysteine compound to the coffee seed oil being 1 :200 to 12:1 , the expression of TXNRD1 gene is synergistically elevated.
  • the present invention is directed to a personal care composition comprising carboxymethyl cysteine compound and coffee seed oil, wherein the weight ratio of the carboxymethyl cysteine compound to the coffee seed oil is 1 :200 to 12:1.
  • the present invention is directed to a method for providing antioxidation, and/or anti-aging benefit; reducing oxidative stress; and/or upregulating the expression of thioredoxin reductase 1 gene, comprising a step of topically applying to the skin the composition of the present invention.
  • the present invention is directed to use of the composition of the present invention for providing antioxidation and/or anti-aging benefit; reducing oxidative stress; and/or upregulating the expression of thioredoxin reductase 1 gene.
  • the carboxymethyl cysteine compound refers to compound selected from carboxymethyl cysteine, salt of carboxymethyl cysteine, ester of carboxymethyl cysteine, amide of carboxymethyl cysteine or a mixture thereof.
  • the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and/or salt of carboxymethyl cysteine. More preferably, the carboxymethyl cysteine compound comprises carboxymethyl cysteine, and/or salt of carboxymethyl cysteine.
  • carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine. Still even more preferably the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate and most preferably, the carboxymethyl cysteine compound is lysine carboxymethyl cysteinate.
  • the carboxymethyl cysteine compound is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001 %, still even more preferably at least 0.01%, and most preferably at least 0.1 % by weight of the composition.
  • the carboxymethyl cysteine compound is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition.
  • the lysine carboxymethyl cysteinate is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition.
  • the lysine carboxymethyl cysteinate is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001%, still even more preferably at least 0.01 %, and most preferably at least 0.1% by weight of the composition.
  • Coffee seed oil is the oil extracted from the beans of certain Coffea species. It can be extracted from unroasted coffee beans or roasted coffee beans. Coffee seed oil is rich in saturated fatty acids, unsaturated fatty acids and tocopherols. Due to these properties, coffee seed oil is sometimes used in skin care products.
  • the composition of coffee seed oil varies according to the process of manufacture and Coffea species. For example, unroasted coffee seed oil may contain higher level of fatty acids, vitamins and caffeine.
  • Koffee’UPTM from Givaudan, is oil of roasted Coffea arabica seeds. It is manufactured from drying spent coffee grounds followed by supercritical CO2 extraction. Koffee’UPTM is claimed to protect the skin and help the skin to stay hydrated.
  • the composition of the present invention comprises coffee seed oil.
  • the coffee seed oil is extracted from roasted seeds of coffee, more preferably from roasted seeds of coffee selected from coffea arabica, coffea canephora and coffea liberie, and most preferably from roasted seeds of coffee from coffea arabica.
  • the coffee seed oil is obtained by supercritical fluid extraction, more preferably supercritical CO2 extraction.
  • the coffee seed oil is employed in the composition in an amount of 0.00001 to 5% by weight of the composition, more preferably in an amount of 0.0001 to 2%, even more preferably from 0.005 to 0.5% and most preferably in an amount of 0.02 to 0.2% by weight of the composition.
  • the weight ratio of the carboxymethyl cysteine compound to the coffee seed oil is 1 :200 to 12:1 , more preferably 1 :50 to 12:1 , even more preferably 1 :12 to 3:1 , still even more preferably 1 :6 to 1.5:1 , and most preferably 4:1 to 1 :1.
  • the amount of extract in the present invention refers to the amount of extracted ingredients from the plant, excluding the weight of the extract solvent.
  • the composition comprises Vitamin B3 compounds (including derivatives of vitamin B3).
  • the vitamin B3 compounds comprises niacin, nicotinic acid, niacinamide or a mixture thereof.
  • the most preferred vitamin B3 compound is niacinamide.
  • Amount of Vitamin B3 compounds may be 0.1 to 10%, preferably 0.5 to 5% by weight of the composition.
  • the composition comprises a glutamate source selected from the group consisting of glutamine, glutamine ester, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and/or salt of pyroglutamic acid. Even more preferably, the composition comprises sodium salt of pyroglutamic acid.
  • the glutamate source is present in amount of 0.0001 to 10% by weight of the composition, more preferably 0.001 to 6%, even more preferably 0.01 to 3% by weight of the composition.
  • the composition may optionally comprise whitening pigment.
  • Whitening pigments are typically particles of high refractive index materials.
  • the whitening pigment may have a refractive index of greater than 1.3, more preferably greater than 1.8 and most preferably from 2.0 to 2.7.
  • Examples of such whitening pigment are those comprising bismuth oxy-chloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminium oxide, zinc oxide or combinations thereof. More preferred whitening pigment are particles comprising titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide or a combination thereof.
  • Even more preferred whitening pigment are particles comprising zinc oxide, zirconium oxide, titanium dioxide or a combination thereof as these materials have especially high refractive index. Still even more preferably the whitening pigment is selected from titanium dioxide, zinc oxide or a mixture thereof and most preferred whitening pigment is titanium dioxide.
  • the average diameter of whitening pigment is typical from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm and still even more preferably from 100 to 300 nm.
  • Amount of whitening pigment may be 0.1 to 15%, preferably 0.5 to 5% by weight of the composition.
  • the composition comprises polyhydric alcohol.
  • Polyhydric alcohols may be selected from group of glycerin, propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1 ,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or a mixture thereof.
  • Most preferred polyhydric alcohol is glycerol known also as glycerin.
  • the amount of polyhydric alcohol may range anywhere from 0.1 to 20%, preferably 0.5 to 15% and more preferably 2 and 10% by weight of the composition.
  • Illustrative triglycerides but not limiting are sunflower seed oil, cotton oil, canola oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil and mixtures thereof. Mono- and di- glycerides may also be useful. Particularly preferable are glyceryl monostearate and glyceryl distearate.
  • the composition comprises moisturizing agents.
  • moisturizing agents includes, petrolatum, aquaporin manipulating actives, oat kernel flour, substituted urea like hydroxyethyl urea, hyaluronic acid and/or its precursor N-acetyl glucosamine, hyaluronic acid and/or its precursor N-acetyl glucosamine, or a mixture thereof.
  • compositions may include thickeners. These may be selected from cellulosics, natural gums and acrylic polymers but not limited by this thickening agent types.
  • cellulosics sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof.
  • Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof.
  • acrylic thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, llltrez, Aqua SF-1 and Aqua SF-2 available from the Lubrizol Corporation.
  • Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the compositions.
  • compositions of the invention may further include 0.5 to 10% by weight of sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene/Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.
  • sequestering agents such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures
  • opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene/Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.
  • the composition may comprise water in amount of 10 to 96% by weight of the composition, more preferably from 25 to 92%, even more preferably from 42 to 88%, most preferably from 55 to 82% by weight of the composition.
  • the composition has a viscosity of at least 10 mPa s, more preferably in the range 30 to 10000 mPa s, even more preferably 50 to 5000 mPa s, and most preferably 100 to 2000 mPa s, when measured at 20 degrees C at a relatively high shear rate of about 20 s -1 .
  • the composition is an emulsion, more preferably an oil-in-water emulsion.
  • the composition is a fluid liquid at 25 °C and atmospheric pressure.
  • the personal care composition is a skin care composition.
  • Skin care composition refers to a composition suitable for topical application to human skin, including leave-on and wash-off products but preferably leave-on compositions.
  • leave-on as used with reference to compositions herein means a composition that is applied to or rubbed on the skin, and left thereon.
  • wash-off as used with reference to compositions herein means a skin cleanser that is applied to or rubbed on the skin and rinsed off substantially immediately subsequent to application.
  • skin as used herein includes the skin on the face, neck, chest, abdomen, back, arms, under arms, hands, and legs.
  • skin means includes the skin on the face and under arms, more preferably skin means skin on the face other than lips and eyelids.
  • the composition is particularly preferably a moisturizer rather than a make-up product.
  • the composition is a topical composition.
  • the composition may be in the form of cream, lotion, ointment, solution, suspension, emulsion, paste, gel, powder, powder foundation, emulsion foundation, wax foundation, or spray. More preferably, the composition may be formulated in the form of cream, lotion, ointment, emulsion, gel, or a spray.
  • the use is non-therapeutic.
  • the method is non-therapeutic.
  • non-therapeutic typically means for cosmetic purposes and not curative or therapeutic purposes.
  • Koffee’UPTM (coffea arabica seed oil) used in the examples was obtained from Givaudan France SAS.
  • the coffea arabica seed for preparing Koffee’UPTM was not obtained from India.
  • This Example demonstrates the synergistic upregulation of gene expression by combining carboxymethyl cysteine compound and coffee seed oil.
  • the normal human epidermal keratinocytes (NHEK, Archgene Biotechnology, Shanghai, China, Lot: NHS-2021-006) were incubated in medium together with or without actives for 24 hours. After incubation, the total RNA for each NHEK was extracted using Qiagen Mini RNeasy kit (Qiagen, Cat.74106) according to manufacturer’s protocol.
  • Amplification of the gene encoding the TXNRD1 (Thioredoxin reductase 1) gene was performed with RT-PCR reagent (Universal SYBR Green Fast qPCR Mix kit (Cat. RK21203, ABclonal)) on the ABI Vii 7 Real-Time PCR Systems (Applied Biosystems, Thermo fisher scientific, Carlsbad, CA, USA).
  • the Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta (YWHAZ) was selected as the housekeeping gene and all data on relative expression of the target genes was normalized to YWHAZ. The fold changes in expression were calculated relative to the blank control (medium having no active). All tests were conducted at least three times and Table 1 shows the fold changes in gene expression of TXNRD1.
  • the level of the active is based on the medium. a: significantly better (p ⁇ 0.05) than either of single active at same level.
  • Table 1 it was surprisingly found that the fold change when combining lysine carboxymethyl cysteinate and coffee seed oil with a specific ratio was significantly higher than the product of the fold change for lysine carboxymethyl cysteinate only and that for coffee seed oil only.
  • the expression of TXNRD1 was synergistically elevated by combining lysine carboxymethyl cysteinate and coffee seed oil within the range of the present invention. In contrast, the expression of TXNRD1 gene was not elevated when combining lysine carboxymethyl cysteinate and coffee seed oil outside the range of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)

Abstract

Disclosed is a personal care composition comprising carboxymethyl cysteine compound and coffee seed oil, wherein the weight ratio of the carboxymethyl cysteine compound to the coffee seed oil is 1:200 to 12:1.

Description

PERSONAL CARE COMPOSITION
Field of the Invention
The present invention relates to a personal care composition comprising a carboxymethyl cysteine compound and coffee seed oil. Surprisingly, such composition is capable of providing synergistic antioxidation effect. of the Invention
Human skin may provide physicochemical protection against environmental insults through its barrier function, mechanical strength and imperviousness to water. It is constantly exposed to harmful environments and extreme conditions, such as ultra-violet radiation, blue light, pollution etc. Such harmful environmental applications may cause excessive generation of reactive oxygen species (ROS) thereby resulting in an oxidative stress condition. Oxidative stress may affect our skin in many ways including signs of premature aging such as wrinkles, fine lines, uneven skin tone.
Thioredoxin reductase 1 (TXNRD1) is an oxidoreductase encoded by the TXNRD1 gene in humans and a member of the antioxidant thioredoxin system. TXNRD1 plays an important role in oxidative stress control. It reduces and activates thioredoxin, an oxidoreductase containing a dithiol-disulfide active site. Thioredoxin binds ROS before they can harm cells and thus protects cells against oxidative stress.
The present inventors have recognized there is a need to develop a personal care composition which is capable of improving the gene expression of TXNRD1. Therefore, the present inventors have developed a personal care composition comprising carboxymethyl cysteine compound and coffee seed oil. It was surprisingly found that by combining carboxymethyl cysteine compound with coffee seed oil with weight ratio of the carboxymethyl cysteine compound to the coffee seed oil being 1 :200 to 12:1 , the expression of TXNRD1 gene is synergistically elevated.
Summary of the Invention
In a first aspect, the present invention is directed to a personal care composition comprising carboxymethyl cysteine compound and coffee seed oil, wherein the weight ratio of the carboxymethyl cysteine compound to the coffee seed oil is 1 :200 to 12:1. In a second aspect, the present invention is directed to a method for providing antioxidation, and/or anti-aging benefit; reducing oxidative stress; and/or upregulating the expression of thioredoxin reductase 1 gene, comprising a step of topically applying to the skin the composition of the present invention.
In a third aspect, the present invention is directed to use of the composition of the present invention for providing antioxidation and/or anti-aging benefit; reducing oxidative stress; and/or upregulating the expression of thioredoxin reductase 1 gene.
All other aspects of the present invention will more readily become apparent upon considering the detailed description and examples which follow.
Detailed Description of the Invention
Except in the examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material or conditions of reaction, physical properties of materials and/or use may optionally be understood as modified by the word “about”.
All amounts are by weight of the composition, unless otherwise specified.
It should be noted that in specifying any range of values, any particular upper value can be associated with any particular lower value.
For the avoidance of doubt, the word “comprising” is intended to mean “including” but not necessarily “consisting of’ or “composed of’. In other words, the listed steps or options need not be exhaustive.
The disclosure of the invention as found herein is to be considered to cover all embodiments as found in the claims as being multiply dependent upon each other irrespective of the fact that claims may be found without multiple dependency or redundancy.
Where a feature is disclosed with respect to a particular aspect of the invention (for example a composition of the invention), such disclosure is also to be considered to apply to any other aspect of the invention (for example a method of the invention) mutatis mutandis. The carboxymethyl cysteine compound refers to compound selected from carboxymethyl cysteine, salt of carboxymethyl cysteine, ester of carboxymethyl cysteine, amide of carboxymethyl cysteine or a mixture thereof. Preferably, the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and/or salt of carboxymethyl cysteine. More preferably, the carboxymethyl cysteine compound comprises carboxymethyl cysteine, and/or salt of carboxymethyl cysteine. Even more preferably, carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine. Still even more preferably the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate and most preferably, the carboxymethyl cysteine compound is lysine carboxymethyl cysteinate.
Preferably, the carboxymethyl cysteine compound is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001 %, still even more preferably at least 0.01%, and most preferably at least 0.1 % by weight of the composition. Preferably, the carboxymethyl cysteine compound is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition.
Preferably, the lysine carboxymethyl cysteinate is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition. Preferably, the lysine carboxymethyl cysteinate is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001%, still even more preferably at least 0.01 %, and most preferably at least 0.1% by weight of the composition.
Coffee seed oil is the oil extracted from the beans of certain Coffea species. It can be extracted from unroasted coffee beans or roasted coffee beans. Coffee seed oil is rich in saturated fatty acids, unsaturated fatty acids and tocopherols. Due to these properties, coffee seed oil is sometimes used in skin care products. The composition of coffee seed oil varies according to the process of manufacture and Coffea species. For example, unroasted coffee seed oil may contain higher level of fatty acids, vitamins and caffeine.
Koffee’UP™, from Givaudan, is oil of roasted Coffea arabica seeds. It is manufactured from drying spent coffee grounds followed by supercritical CO2 extraction. Koffee’UP™ is claimed to protect the skin and help the skin to stay hydrated. The composition of the present invention comprises coffee seed oil. Preferably, the coffee seed oil is extracted from roasted seeds of coffee, more preferably from roasted seeds of coffee selected from coffea arabica, coffea canephora and coffea liberie, and most preferably from roasted seeds of coffee from coffea arabica. Preferably, the coffee seed oil is obtained by supercritical fluid extraction, more preferably supercritical CO2 extraction.
Preferably, the coffee seed oil is employed in the composition in an amount of 0.00001 to 5% by weight of the composition, more preferably in an amount of 0.0001 to 2%, even more preferably from 0.005 to 0.5% and most preferably in an amount of 0.02 to 0.2% by weight of the composition.
The weight ratio of the carboxymethyl cysteine compound to the coffee seed oil is 1 :200 to 12:1 , more preferably 1 :50 to 12:1 , even more preferably 1 :12 to 3:1 , still even more preferably 1 :6 to 1.5:1 , and most preferably 4:1 to 1 :1.
For sake of clarity, the amount of extract in the present invention refers to the amount of extracted ingredients from the plant, excluding the weight of the extract solvent.
Preferably, the composition comprises Vitamin B3 compounds (including derivatives of vitamin B3). The vitamin B3 compounds comprises niacin, nicotinic acid, niacinamide or a mixture thereof. The most preferred vitamin B3 compound is niacinamide. Amount of Vitamin B3 compounds may be 0.1 to 10%, preferably 0.5 to 5% by weight of the composition.
Preferably, the composition comprises a glutamate source selected from the group consisting of glutamine, glutamine ester, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and/or salt of pyroglutamic acid. Even more preferably, the composition comprises sodium salt of pyroglutamic acid. Preferably, the glutamate source is present in amount of 0.0001 to 10% by weight of the composition, more preferably 0.001 to 6%, even more preferably 0.01 to 3% by weight of the composition.
The composition may optionally comprise whitening pigment. Whitening pigments are typically particles of high refractive index materials. For example, the whitening pigment may have a refractive index of greater than 1.3, more preferably greater than 1.8 and most preferably from 2.0 to 2.7. Examples of such whitening pigment are those comprising bismuth oxy-chloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminium oxide, zinc oxide or combinations thereof. More preferred whitening pigment are particles comprising titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide or a combination thereof. Even more preferred whitening pigment are particles comprising zinc oxide, zirconium oxide, titanium dioxide or a combination thereof as these materials have especially high refractive index. Still even more preferably the whitening pigment is selected from titanium dioxide, zinc oxide or a mixture thereof and most preferred whitening pigment is titanium dioxide. The average diameter of whitening pigment is typical from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm and still even more preferably from 100 to 300 nm. Amount of whitening pigment may be 0.1 to 15%, preferably 0.5 to 5% by weight of the composition.
Preferably, the composition comprises polyhydric alcohol. Polyhydric alcohols may be selected from group of glycerin, propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1 ,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or a mixture thereof. Most preferred polyhydric alcohol is glycerol known also as glycerin. The amount of polyhydric alcohol may range anywhere from 0.1 to 20%, preferably 0.5 to 15% and more preferably 2 and 10% by weight of the composition.
Preferably, the composition comprises emollient materials. Suitable emollient materials include silicones, hydrocarbons, triglycerides or a mixture thereof. These silicones may be organic, silicone-containing or fluorine-containing, volatile or non-volatile, polar or non-polar. Hydrocarbons may include mineral oil, petrolatum and polyalpha-olefins. Examples of preferred volatile hydrocarbons include polydecanes such as isododecane and isodecane (e.g. Permethyl- 99A which is available from Presperse Inc.) and the C7-C8 through C12-C15 isoparaffins (such as the Isopar Series available from Exxon Chemicals). Illustrative triglycerides but not limiting are sunflower seed oil, cotton oil, canola oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil and mixtures thereof. Mono- and di- glycerides may also be useful. Particularly preferable are glyceryl monostearate and glyceryl distearate.
Preferably, the composition comprises moisturizing agents. Particularly preferred moisturizing agents includes, petrolatum, aquaporin manipulating actives, oat kernel flour, substituted urea like hydroxyethyl urea, hyaluronic acid and/or its precursor N-acetyl glucosamine, hyaluronic acid and/or its precursor N-acetyl glucosamine, or a mixture thereof.
Some compositions may include thickeners. These may be selected from cellulosics, natural gums and acrylic polymers but not limited by this thickening agent types. Among the cellulosics are sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof. Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof. Among the acrylic thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, llltrez, Aqua SF-1 and Aqua SF-2 available from the Lubrizol Corporation. Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the compositions.
In addition, the compositions of the invention may further include 0.5 to 10% by weight of sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene/Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.
The composition may comprise water in amount of 10 to 96% by weight of the composition, more preferably from 25 to 92%, even more preferably from 42 to 88%, most preferably from 55 to 82% by weight of the composition.
Preferably, the composition has a viscosity of at least 10 mPa s, more preferably in the range 30 to 10000 mPa s, even more preferably 50 to 5000 mPa s, and most preferably 100 to 2000 mPa s, when measured at 20 degrees C at a relatively high shear rate of about 20 s-1.
Preferably, the composition is an emulsion, more preferably an oil-in-water emulsion. Preferably the composition is a fluid liquid at 25 °C and atmospheric pressure.
Preferably, the personal care composition is a skin care composition. Skin care composition refers to a composition suitable for topical application to human skin, including leave-on and wash-off products but preferably leave-on compositions. The term “leave-on” as used with reference to compositions herein means a composition that is applied to or rubbed on the skin, and left thereon. The term “wash-off” as used with reference to compositions herein means a skin cleanser that is applied to or rubbed on the skin and rinsed off substantially immediately subsequent to application. The term "skin" as used herein includes the skin on the face, neck, chest, abdomen, back, arms, under arms, hands, and legs. Preferably “skin” means includes the skin on the face and under arms, more preferably skin means skin on the face other than lips and eyelids. The composition is particularly preferably a moisturizer rather than a make-up product. Preferably, the composition is a topical composition. Preferably, the composition may be in the form of cream, lotion, ointment, solution, suspension, emulsion, paste, gel, powder, powder foundation, emulsion foundation, wax foundation, or spray. More preferably, the composition may be formulated in the form of cream, lotion, ointment, emulsion, gel, or a spray.
Preferably the use is non-therapeutic. Preferably the method is non-therapeutic. The term non- therapeutic typically means for cosmetic purposes and not curative or therapeutic purposes.
The following examples are provided to facilitate an understanding of the invention. The examples are not intended to limit the scope of the claims.
Examples
Materials
* Koffee’UP™ (coffea arabica seed oil) used in the examples was obtained from Givaudan France SAS. The coffea arabica seed for preparing Koffee’UP™ was not obtained from India.
Example 1
This Example demonstrates the synergistic upregulation of gene expression by combining carboxymethyl cysteine compound and coffee seed oil.
The normal human epidermal keratinocytes (NHEK, Archgene Biotechnology, Shanghai, China, Lot: NHS-2021-006) were incubated in medium together with or without actives for 24 hours. After incubation, the total RNA for each NHEK was extracted using Qiagen Mini RNeasy kit (Qiagen, Cat.74106) according to manufacturer’s protocol.
The extracted RNA was quantified using Nanodrop 2000 spectrometer (Thermo Fisher Scientific, Waltham, MA, US) and reverse transcribed to generate the template cDNA using the ABScript III RT Mast Mix (Cat. BK20428, ABclonal) according to manufacturer’s protocol. Amplification of the gene encoding the TXNRD1 (Thioredoxin reductase 1) gene was performed with RT-PCR reagent (Universal SYBR Green Fast qPCR Mix kit (Cat. RK21203, ABclonal)) on the ABI Vii 7 Real-Time PCR Systems (Applied Biosystems, Thermo fisher scientific, Carlsbad, CA, USA). The Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta (YWHAZ) was selected as the housekeeping gene and all data on relative expression of the target genes was normalized to YWHAZ. The fold changes in expression were calculated relative to the blank control (medium having no active). All tests were conducted at least three times and Table 1 shows the fold changes in gene expression of TXNRD1.
Table 1
#: The level of the active is based on the medium. a: significantly better (p<0.05) than either of single active at same level. As demonstrated in Table 1 , it was surprisingly found that the fold change when combining lysine carboxymethyl cysteinate and coffee seed oil with a specific ratio was significantly higher than the product of the fold change for lysine carboxymethyl cysteinate only and that for coffee seed oil only. The expression of TXNRD1 was synergistically elevated by combining lysine carboxymethyl cysteinate and coffee seed oil within the range of the present invention. In contrast, the expression of TXNRD1 gene was not elevated when combining lysine carboxymethyl cysteinate and coffee seed oil outside the range of the present invention.

Claims

Claims
1. A personal care composition comprising carboxymethyl cysteine compound and coffee seed oil, wherein the weight ratio of the carboxymethyl cysteine compound to the coffee seed oil is 1 :200 to 12:1.
2. The composition according to claim 1 wherein the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and/or salt of carboxymethyl cysteine.
3. The composition according to claim 2 wherein the carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine and preferably the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate.
4. The composition according to any one of the preceding claims wherein the carboxymethyl cysteine compound is present in amount of at least 0.00001% and no greater than 10% by weight of the composition, preferably carboxymethyl cysteine compound is present in amount of at least 0.01% and no greater than 3% by weight of the composition.
5. The composition according to any one of the preceding claims wherein the coffee seed oil is extracted from roasted seeds of coffee, more preferably from roasted seeds of coffee selected from coffea arabica, coffea canephora and coffea liberie, and most preferably from roasted seeds of coffee from coffea arabica.
6. The composition according to any one of the preceding claims wherein the amount of the coffee seed oil is in the range of 0.00001 to 5% by weight of the composition, preferably in the range of 0.02 to 0.2% by weight of the composition.
7. The composition according to any one of the preceding claims wherein the weight ratio of the carboxymethyl cysteine compound to the coffee seed oil is 1 :50 to 12:1 , preferably 1 :12 to 3:1.
8. The composition according to any one of the preceding claims wherein the composition is an emulsion, preferably an oil-in-water emulsion. The composition according to any one of the preceding claims wherein the composition is a fluid liquid at 25 °C and atmospheric pressure. The composition according to any one of the preceding claims wherein the composition comprises water in amount of 10 to 96% by weight of the composition, preferably from 42 to 88% by weight of the composition. A method of providing antioxidation and/or anti-aging benefit; reducing oxidative stress; and/or upregulating the expression of thioredoxin reductase 1 gene, comprising a step of topically applying to the skin the composition of any one of the preceding claims. Use of the composition of any one of the preceding claims 1 to 10 for providing antioxidation and/or anti-aging benefit; reducing oxidative stress; and/or upregulating the expression of thioredoxin reductase 1 gene.
EP23790589.8A 2022-11-11 2023-10-16 Personal care composition Pending EP4615403A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022131249 2022-11-11
EP22212378 2022-12-09
PCT/EP2023/078586 WO2024099688A1 (en) 2022-11-11 2023-10-16 Personal care composition

Publications (1)

Publication Number Publication Date
EP4615403A1 true EP4615403A1 (en) 2025-09-17

Family

ID=88466709

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23790589.8A Pending EP4615403A1 (en) 2022-11-11 2023-10-16 Personal care composition

Country Status (5)

Country Link
EP (1) EP4615403A1 (en)
JP (1) JP2025535576A (en)
CN (1) CN120187402A (en)
MX (1) MX2025005282A (en)
WO (1) WO2024099688A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1312377B1 (en) * 1999-03-05 2002-04-15 Uni Ci S R L COMPOSITIONS BASED ON TIOTIC ACID, CISTEIN AND / OR N-ACETYL CISTEINADA USE IN PHARMACEUTICAL, DIETETIC AND COSMETIC PREPARATIONS
BRPI0602842A8 (en) * 2006-07-20 2017-07-25 Chemyunion Quim Ltda USE OF GREEN COFFEE OIL (COFFEA ARABICA) IN COSMETIC AND PHARMACEUTICAL FORMULATIONS FOR THE MAINTENANCE OF SKIN PROPERTIES

Also Published As

Publication number Publication date
JP2025535576A (en) 2025-10-24
CN120187402A (en) 2025-06-20
WO2024099688A1 (en) 2024-05-16
MX2025005282A (en) 2025-06-02

Similar Documents

Publication Publication Date Title
EP4456868B1 (en) Personal care composition
WO2023126169A1 (en) Use of carboxymethyl cysteine compound
WO2024099688A1 (en) Personal care composition
EP4456863B1 (en) Personal care composition
WO2023126161A1 (en) A personal care or pharmaceutical composition
WO2024099689A1 (en) A personal care composition
WO2026057270A1 (en) A personal care composition
EP4735119A1 (en) A personal care composition
WO2025002724A1 (en) Personal care composition comprising a carboxymethyl cysteine compound and a silymarin compound
WO2026087109A1 (en) Personal care composition based on an acetyl aminoacid compound and a cystine compound
WO2026087117A1 (en) Personal care composition based on carboxymethyl cysteine compound and acetyl methionine compound
WO2025002686A1 (en) A personal care composition comprising a carboxymethyl cysteine compound and an extract of engelhardtia genus
WO2025040355A1 (en) A personal care composition
WO2026068130A1 (en) Personal care composition
WO2025040354A1 (en) A personal care composition
EP4615402A1 (en) A personal care composition
WO2025002688A1 (en) A personal care composition based on carboxymethyl cysteine compound and rosmarinic acid or salt and ester thereof
WO2025003016A1 (en) Personal care composition comprising a carboxymethyl cysteine compound and a creatine compound
EP4734934A1 (en) Personal care composition based on carboxymethyl cystein compound and carotenoid or ester thereof
EP4615404A1 (en) A personal care composition
WO2025002727A1 (en) A personal care composition
WO2026027147A1 (en) A personal care composition
WO2026057269A1 (en) A personal care composition
EP4734947A1 (en) A personal care composition

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250407

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNILEVER IP HOLDINGS B.V.

Owner name: UNILEVER GLOBAL IP LIMITED

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)